M

MoonLake Immunotherapeutics
D

MLTX

18.020
USD
-0.13
(-0.72%)
مغلق
حجم التداول
37,347
الربح لكل سهم
-3
العائد الربحي
-
P/E
-5
حجم السوق
1,276,670,166
أصول ذات صلة المقالات

العنوان: MoonLake Immunotherapeutics

القطاع: Healthcare
الصناعة: Biotechnology
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatologyand rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.